

Laurent Kodjikian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4267127/publications.pdf>

Version: 2024-02-01

166
papers

4,337
citations

109321

35
h-index

155660

55
g-index

196
all docs

196
docs citations

196
times ranked

3522
citing authors

#	ARTICLE	IF	CITATIONS
1	The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. <i>Acta Ophthalmologica</i> , 2023, 101, .	1.1	5
2	Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1109-1115.	1.8	4
3	Early Predictive Factors of Visual Loss at 1 Year in Neovascular Age-Related Macular Degeneration under Anti-Vascular Endothelial Growth Factor. <i>Ophthalmology Retina</i> , 2022, 6, 109-115.	2.4	7
4	Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study. <i>European Journal of Ophthalmology</i> , 2022, 32, 2845-2856.	1.3	5
5	Diagnostic value of lumbar puncture for the etiological assessment of uveitis: a retrospective cohort of 188 patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 1651-1662.	1.9	1
6	Intravitreal Corticosteroid Implantation in Diabetic Macular Edema: Updated European Consensus Guidance on Monitoring and Managing Intraocular Pressure. <i>Ophthalmology and Therapy</i> , 2022, 11, 15-34.	2.3	8
7	Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm. <i>European Journal of Ophthalmology</i> , 2022, 32, 1890-1899.	1.3	17
8	Age-Related Macular Degeneration: New Insights in Diagnosis, Treatment, and Prevention. <i>Journal of Clinical Medicine</i> , 2022, 11, 1064.	2.4	0
9	Non-Cancer Effects following Ionizing Irradiation Involving the Eye and Orbit. <i>Cancers</i> , 2022, 14, 1194.	3.7	6
10	Risk Factors for COVID-19 Associated Mucormycosis: The Ophthalmologist's Perspective. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 271.	3.5	5
11	Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1834.	2.4	6
12	Ocular sarcoidosis. , 2022, , 267-284.		0
13	Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 603-609.	1.8	3
14	Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAC Study. <i>Pharmaceutics</i> , 2022, 14, 723.	4.5	12
15	Identification of Multidimensional Phenotypes Using Cluster Analysis in Sarcoid Uveitis Patients. <i>American Journal of Ophthalmology</i> , 2022, 242, 107-115.	3.3	4
16	Variation of choroidal thickness in diabetic macular edema: friend or foe?. <i>Acta Ophthalmologica</i> , 2021, 99, e282-e283.	1.1	2
17	Uveitis as an Open Window to Systemic Inflammatory Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 281.	2.4	12
18	Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEx Study. <i>Pharmaceutics</i> , 2021, 13, 194.	4.5	6

#	ARTICLE	IF	CITATIONS
19	LIVEITIS TREATED WITH DEXAMETHASONE IMPLANT. <i>Retina</i> , 2021, 41, 620-629.	1.7	11
20	A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study. <i>Acta Ophthalmologica</i> , 2021, 99, 877-884.	1.1	5
21	Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. <i>Eye</i> , 2021, 35, 2119-2135.	2.1	25
22	Retinal Vascularization Analysis on Optical Coherence Tomography Angiography before and after Intraretinal or Subretinal Fluid Resorption in Exudative Age-Related Macular Degeneration: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1524.	2.4	3
23	Reply to re unexpected amaurosis occurring after peribulbar anesthesia: Exploring the causes in two cases. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110195.	1.3	0
24	One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 1971-1978.	1.8	4
25	The role of future treatments in the management of neovascular age-related macular degeneration in Europe. <i>European Journal of Ophthalmology</i> , 2021, 31, 112067212110183.	1.3	0
26	Cardiac Sarcoidosis Is Uncommon in Patients with Isolated Sarcoid Uveitis: Outcome of 294 Cases. <i>Journal of Clinical Medicine</i> , 2021, 10, 2146.	2.4	5
27	Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An <sc>LOC</sc> network study. <i>American Journal of Hematology</i> , 2021, 96, 823-833.	4.1	18
28	Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid. <i>Journal of Clinical Medicine</i> , 2021, 10, 2425.	2.4	6
29	Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2758.	2.4	42
30	ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 2307-2315.	1.8	4
31	LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS. <i>Retina</i> , 2021, 41, 1438-1445.	1.7	27
32	Development and Validation of a Bayesian Network for Supporting the Etiological Diagnosis of Uveitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3398.	2.4	8
33	SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021, 41, 1901-1910.	1.7	4
34	QUANTITATIVE ANALYSIS OF CHORIOCAPILLARIS ALTERATIONS IN SWEEP-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN DIABETIC PATIENTS. <i>Retina</i> , 2021, 41, 1809-1818.	1.7	10
35	Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4153.	2.4	17
36	Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review. <i>Pharmaceutics</i> , 2021, 13, 72.	4.5	14

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of Aflibercept for the treatment of idiopathic choroidal neovascularization in young patients. <i>Retina</i> , 2021, Publish Ahead of Print, .	1.7	3
38	Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 225-226.	0.8	1
39	Safety of 6000 intravitreal dexamethasone implants. <i>British Journal of Ophthalmology</i> , 2020, 104, 39-46.	3.9	56
40	A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. <i>Ophthalmology</i> , 2020, 127, 377-393.	5.2	40
41	Development of Vitreoretinal Lymphoma in a Patient with Sarcoid Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 647-650.	1.8	6
42	Idiopathic polypoidal choroidal vasculopathy in Caucasians: The POLYON real-life study in 50 naive patients. <i>European Journal of Ophthalmology</i> , 2020, 30, 948-955.	1.3	3
43	Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 521-528.	1.9	34
44	20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas. <i>Melanoma Research</i> , 2020, 30, 272-278.	1.2	4
45	Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study. <i>Acta Diabetologica</i> , 2020, 57, 1413-1421.	2.5	12
46	Factors Associated with Ocular and Extraocular Recovery in 143 Patients with Sarcoid Uveitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3894.	2.4	6
47	Ocular Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 673-688.	2.1	31
48	<p>Trends in Real-World Neovascular AMD Treatment Outcomes in the UK<p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3331-3342.	1.8	29
49	Diagnostic value of lymphopaenia and elevated serum ACE in patients with uveitis. <i>British Journal of Ophthalmology</i> , 2020, 105, bjophthalmol-2020-316563.	3.9	9
50	HYPERAUTOFLUORESCENT SPOTS IN ACUTE OCULAR TOXOPLASMOSIS. <i>Retina</i> , 2020, 40, 2396-2402.	1.7	7
51	Differences in the presentation of stage 1 macular holes illustration by optical coherence tomography. <i>European Journal of Ophthalmology</i> , 2020, 31, 112067212090466.	1.3	1
52	Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study. <i>BMJ Open Ophthalmology</i> , 2020, 5, e000377.	1.6	9
53	Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). <i>PLoS ONE</i> , 2020, 15, e0228918.	2.5	4
54	Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-8.	1.3	11

#	ARTICLE	IF	CITATIONS
55	Increased choroidal thickness: a new indicator for monitoring diabetic macular oedema recurrence. <i>Acta Ophthalmologica</i> , 2020, 98, e968-e974.	1.1	9
56	Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. <i>PLoS ONE</i> , 2020, 15, e0230560.	2.5	14
57	Unexpected amaurosis occurring after peribulbar anesthesia: Exploring the causes in two cases. <i>European Journal of Ophthalmology</i> , 2020, , 112067212098439.	1.3	4
58	Incidence of Irvine Gass Syndrome after Phacoemulsification with Spectral-Domain Optical Coherence Tomography. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1224-1231.	1.8	15
59	Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 2495-2503.	1.9	25
60	Uveitis: Autoimmunity and beyond. <i>Autoimmunity Reviews</i> , 2019, 18, 102351.	5.8	53
61	Pro Re Nata Dexamethasone Implant for Treatment-Naive Phakic Eyes with Diabetic Macular Edema. <i>Ophthalmology Retina</i> , 2019, 3, 929-937.	2.4	10
62	Acute Retinal Necrosis: Virological Features Using Quantitative Polymerase Chain Reaction, Therapeutic Management, and Clinical Outcomes. <i>American Journal of Ophthalmology</i> , 2019, 208, 376-386.	3.3	28
63	¹⁸ F-fluorodeoxyglucose positron emission tomography is useful for the diagnosis of intraocular sarcoidosis in patients with a normal CT scan. <i>British Journal of Ophthalmology</i> , 2019, 103, 1650-1655.	3.9	14
64	Hypertensive choroidopathy: Multimodal imaging and the contribution of wide-field swept-source oct-angiography. <i>American Journal of Ophthalmology Case Reports</i> , 2019, 13, 131-135.	0.7	19
65	First-line treatment algorithm and guidelines in center-involving diabetic macular edema. <i>European Journal of Ophthalmology</i> , 2019, 29, 573-584.	1.3	58
66	Optical Coherence Tomography Angiography Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2019, 201, 82-83.	3.3	5
67	Expert opinion on the use of biological therapy in non-infectious uveitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 477-490.	3.1	51
68	The Lens Opacities Classification System III Grading in Irradiated Uveal Melanomas to Characterize Proton Therapy-Induced Cataracts. <i>American Journal of Ophthalmology</i> , 2019, 201, 63-71.	3.3	10
69	XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases. <i>Journal of Glaucoma</i> , 2019, 28, e5-e9.	1.6	24
70	Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 699-707.	1.9	10
71	Uveitis of Unknown Etiology: Clinical and Outcome features. A Retrospective Analysis of 355 Patients. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1251-1258.	1.8	4
72	New concepts in the diagnosis and management of choroidal metastases. <i>Progress in Retinal and Eye Research</i> , 2019, 68, 144-176.	15.5	95

#	ARTICLE	IF	CITATIONS
73	EVALUATION OF OBSTRUCTIVE SLEEP APNEA SYNDROME AS A RISK FACTOR FOR DIABETIC MACULAR EDEMA IN PATIENTS WITH TYPE II DIABETES. <i>Retina</i> , 2019, 39, 274-280.	1.7	23
74	XEN gel stent: a total delayed-onset postoperative hyphema. <i>International Journal of Ophthalmology</i> , 2019, 12, 1224-1226.	1.1	5
75	Sub-Tenon anesthesia, maintained oral anticoagulant and antiplatelet therapies and vitreoretinal surgery: About 68 cases. <i>Journal Francais D'Ophthalmologie</i> , 2019, 42, e239-e240.	0.4	1
76	The Pattern of Recurrence in Diabetic Macular Edema Treated by Dexamethasone Implant: The PREDIAMEX Study. <i>Ophthalmology Retina</i> , 2018, 2, 567-573.	2.4	22
77	PREDICTORS OF ONE-YEAR VISUAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2018, 38, 1492-1499.	1.7	17
78	INTRAOCCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION. <i>Retina</i> , 2018, 38, 2343-2349.	1.7	18
79	Choroidal neovascularisation triggered multiple evanescent white dot syndrome (MEWDS) in predisposed eyes. <i>British Journal of Ophthalmology</i> , 2018, 102, 971-976.	3.9	18
80	Evaluation of efficacy and safety of dexamethasone intravitreal implants before and after vitrectomy in a real-life study. <i>Acta Ophthalmologica</i> , 2018, 96, e544-e546.	1.1	5
81	A Comparative Study of Characteristics and Outcomes of Patients with Proved and Suggested Sarcoid Uveitis Occurring after Ophthalmic Procedure. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-7.	1.3	0
82	Intra- and subretinal neovascularization following radiation therapy: Contribution of OCT-angiography. <i>Journal Francais D'Ophthalmologie</i> , 2018, 41, e481-e483.	0.4	4
83	Real study: Re-treatment evaluated on visual acuity for Lucentis Â® in neovascular AMD. <i>Journal Francais D'Ophthalmologie</i> , 2018, 41, 397-401.	0.4	1
84	Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. <i>BioMed Research International</i> , 2018, 2018, 1-16.	1.9	49
85	Optical Coherence Tomography Angiography Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2018, 194, 26-34.	3.3	86
86	Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 2271-2271.	1.9	2
87	Evaluation of Efficacy and Safety of Dexamethasone Intravitreal Implants of Vitrectomized and Nonvitrectomized Eyes in a Real-World Study. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 596-602.	1.4	15
88	Intravitreal Dexamethasone Implant (OzurdexÂ®) for Exudative Retinal Detachment after Proton Beam Therapy for Choroidal Melanoma. <i>European Journal of Ophthalmology</i> , 2017, 27, 596-600.	1.3	5
89	REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT. <i>Retina</i> , 2017, 37, 753-760.	1.7	99
90	SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX). <i>Retina</i> , 2017, 37, 1352-1359.	1.7	120

#	ARTICLE	IF	CITATIONS
91	Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). American Journal of Ophthalmology, 2017, 178, 176-185.	3.3	69
92	Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis. British Journal of Ophthalmology, 2017, 101, 856-861.	3.9	51
93	Postoperative Ocular Inflammation: A Single Subconjunctival Injection of XG-102 Compared to Dexamethasone Drops in a Randomized Trial. American Journal of Ophthalmology, 2017, 174, 76-84.	3.3	39
94	Detection of mild papilloedema in posterior uveitis using spectral domain optical coherence tomography. British Journal of Ophthalmology, 2017, 101, 401-405.	3.9	7
95	Management of Irvine-Gass syndrome. Journal Francais D'Ophthalmologie, 2017, 40, 788-792.	0.4	8
96	Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmunity Reviews, 2017, 16, 1254-1264.	5.8	93
97	Serious Adverse Events with Bevacizumab or Ranibizumab for Age-Related Macular Degeneration: Meta-analysis of Individual Patient Data. Ophthalmology Retina, 2017, 1, 375-381.	2.4	11
98	TOLERANCE OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA. Retina, 2017, 37, 173-178.	1.7	14
99	Unusual Presentation of Type 1 Idiopathic Macular Telangiectasia. Case Reports in Ophthalmological Medicine, 2017, 2017, 1-6.	0.5	3
100	Moxifloxacin superior to cefuroxime in reducing bacterial adhesion of <i>Staphylococcus epidermidis</i> on hydrophobic intraocular lenses. Acta Ophthalmologica, 2016, 94, e11-5.	1.1	2
101	Microencapsulation of rifampicin for the prevention of endophthalmitis: In vitro release studies and antibacterial assessment. International Journal of Pharmaceutics, 2016, 505, 262-270.	5.2	5
102	Bevacizumab in age-related macular degeneration: why an off-label treatment is the preferred therapy?. Expert Review of Ophthalmology, 2015, 10, 1-3.	0.6	1
103	Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study. Eye, 2015, 29, 769-775.	2.1	7
104	Uveitis in adults: What do rheumatologists need to know?. Joint Bone Spine, 2015, 82, 308-314.	1.6	24
105	Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. British Journal of Ophthalmology, 2015, 99, 979-983.	3.9	53
106	Clinical features and diagnostic evaluation of 83 biopsy-proven sarcoid uveitis cases. British Journal of Ophthalmology, 2015, 99, 1372-1376.	3.9	44
107	Acute anterior uveitis and undiagnosed spondyloarthritis: usefulness of Berlin criteria. Graefes' Archive for Clinical and Experimental Ophthalmology, 2015, 253, 115-120.	1.9	22
108	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. , 2014, , CD011230.		106

#	ARTICLE	IF	CITATIONS
109	Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1529-1537.	1.9	29
110	Sarcoidosis and uveitis. Autoimmunity Reviews, 2014, 13, 840-849.	5.8	128
111	<i>Staphylococcus epidermidis&/i>&/b>; Biofilm Formation and Structural Organization on Different Types of Intraocular Lenses under in vitro Flow Conditions. Ophthalmic Research, 2013, 50, 83-90.	1.9	9
112	Ocular sarcoidosis: when should labial salivary gland biopsy be performed?. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 855-860.	1.9	22
113	Calculation of Intraocular Lens Surface Free Energy and its Components from Contact Angle Measurements. Ophthalmic Research, 2013, 50, 165-173.	1.9	6
114	Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology, 2013, 120, 2300-2309.	5.2	221
115	Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmologica, 2013, 91, e15-21.	1.1	24
116	Endophthalmitis prophylaxis in cataract surgery: Overview of current practice patterns in 9 European countries. Journal of Cataract and Refractive Surgery, 2013, 39, 1421-1431.	1.5	86
117	Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmunity Reviews, 2013, 12, 774-783.	5.8	79
118	Three hundred and sixty degree retinotomy for retinal detachments with severe proliferative vitreoretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2081-2085.	1.9	26
119	Prise en charge de la DMLA exsudative en 2013. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1339-1346.	0.0	0
120	Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from ¹⁸ F-labelled fluorodeoxyglucose positron emission tomography. British Journal of Ophthalmology, 2012, 96, 99-103.	3.9	39
121	Uveitis and Common Variable Immunodeficiency: Data from the DEF-I Study And Literature Review. Ocular Immunology and Inflammation, 2012, 20, 163-170.	1.8	14
122	Aqueous humor contamination during phacoemulsification in a university teaching hospital. Journal Francais D'Ophthalmologie, 2012, 35, 153-156.	0.4	14
123	Sarcoid-related Uveitis Occurring During Adalimumab Therapy. Ocular Immunology and Inflammation, 2012, 20, 59-60.	1.8	42
124	The Role of Topical Moxifloxacin, a New Antibacterial in Europe, in the Treatment of Bacterial Conjunctivitis. Clinical Drug Investigation, 2011, 31, 543-557.	2.2	16
125	Bacterial Contamination Rate of the Anterior Chamber during Cataract Surgery using Conventional Culture and Eubacterial PCR. European Journal of Ophthalmology, 2010, 20, 365-369.	1.3	10
126	Experimental Intracameral Injection of Vancomycin Microparticles in Rabbits. , 2010, 51, 4125.		11

#	ARTICLE	IF	CITATIONS
127	Inpatient costs of endophthalmitis evaluated for the whole of France. <i>Applied Health Economics and Health Policy</i> , 2010, 8, 53-60.	2.1	4
128	MÃ©lanome uvÃ©al postÃ©rieur (choroÃ©de et/ou corps ciliaire). , 2010, , 127-132.		0
129	Ocular zoonoses. <i>Expert Review of Ophthalmology</i> , 2009, 4, 331-349.	0.6	2
130	Responding letter. <i>Eye</i> , 2009, 23, 1469-1469.	2.1	0
131	Postcataract acute endophthalmitis in France: National prospective survey. <i>Journal of Cataract and Refractive Surgery</i> , 2009, 35, 89-97.	1.5	30
132	Bacterial adhesion to conventional hydrogel and new silicone-hydrogel contact lens materials. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 267-273.	1.9	72
133	Influence of intraocular lens material on the development of acute endophthalmitis after cataract surgery?. <i>Eye</i> , 2008, 22, 184-193.	2.1	14
134	Adherence and kinetics of biofilm formation of <i>Staphylococcus epidermidis</i> to different types of intraocular lenses under dynamic flow conditions. <i>Journal of Cataract and Refractive Surgery</i> , 2008, 34, 153-158.	1.5	30
135	In vitro efficacy of newly designed vancomycin-based microparticles. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 702-708.	1.5	5
136	Survival after primary enucleation for choroidal melanoma: changes induced by the introduction of conservative therapies. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 657-663.	1.9	12
137	A Novel In Vitro Model to Study Staphylococcal Biofilm Formation on Intraocular Lenses under Hydrodynamic Conditions. , 2006, 47, 3410.		28
138	COMBINED PARS PLANA PHACOFRAGMENTATION, VITRECTOMY, AND ARTISAN LENS IMPLANTATION FOR TRAUMATIC SUBLUXATED CATARACTS. <i>Retina</i> , 2006, 26, 909-916.	1.7	23
139	Preparation of vancomycin microparticles: Importance of preparation parameters. <i>International Journal of Pharmaceutics</i> , 2006, 324, 176-184.	5.2	37
140	Ocular manifestations in congenital toxoplasmosis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 14-21.	1.9	64
141	Reactivation of ocular toxoplasmosis during pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 241-242.	2.3	70
142	Endophthalmitis and biomaterials. <i>Acta Ophthalmologica</i> , 2005, 83, 633-633.	0.3	2
143	Survival after primary enucleation of largest uveal melanomas. <i>Acta Ophthalmologica</i> , 2005, 83, 398-398.	0.3	4
144	Atypical VogtÃ©KoyanagiÃ©Harada disease or new uveomeningitic syndrome?. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 263-265.	1.9	0

#	ARTICLE	IF	CITATIONS
145	Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 622-624.	1.9	7
146	Toxic effects of indocyanine green, infracyanine green, and trypan blue on the human retinal pigmented epithelium. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 917-925.	1.9	80
147	Prognostic factors of liver metastases from uveal melanoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 985-993.	1.9	49
148	In vitro influence of vancomycin on adhesion of a Staphylococcus epidermidis strain encoding intercellular adhesion locus ica to intraocular lenses. Journal of Cataract and Refractive Surgery, 2005, 31, 1050-1058.	1.5	14
149	Intraocular microsporidiosis due to in a patient with idiopathic CD4+ T-lymphocytopenia. International Journal of Medical Microbiology, 2005, 294, 529-533.	3.6	30
150	Keratoglobus surgery: penetrating keratoplasty redux. Acta Ophthalmologica, 2004, 82, 625-627.	0.3	11
151	Bilateral rhegmatogenous retinal detachment after external-beam radiotherapy: just a coincidence?. Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242, 523-526.	1.9	5
152	Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer, 2004, 101, 207-208.	4.1	1
153	Intracameral vancomycin and endophthalmitis prophylaxis. Journal of Cataract and Refractive Surgery, 2004, 30, 2030.	1.5	2
154	Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). American Journal of Ophthalmology, 2004, 137, 893-900.	3.3	86
155	Survival after proton-beam irradiation of uveal melanomas. American Journal of Ophthalmology, 2004, 137, 1002-1010.	3.3	56
156	VERTICAL TRANSMISSION OF TOXOPLASMOSIS FROM A CHRONICALLY INFECTED IMMUNOCOMPETENT WOMAN. Pediatric Infectious Disease Journal, 2004, 23, 272-274.	2.0	64
157	Long-Term Ocular Prognosis in 327 Children With Congenital Toxoplasmosis. Pediatrics, 2004, 113, 1567-1572.	2.1	192
158	Intraocular lenses, bacterial adhesion and endophthalmitis prevention: a review. Bio-Medical Materials and Engineering, 2004, 14, 395-409.	0.6	6
159	Familial uveal melanoma: a report on two families and a review of the literature. Acta Ophthalmologica, 2003, 81, 389-395.	0.3	23
160	Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiology and Infection, 2003, 131, 1157-1168.	2.1	59
161	Biofilm Formation on Intraocular Lenses by a Clinical Strain Encoding the <i>ica</i> Locus: A Scanning Electron Microscopy Study. , 2003, 44, 4382.		49
162	Bacterial Adherence of <i>Staphylococcus Epidermidis</i> to Intraocular Lenses: A Bioluminescence and Scanning Electron Microscopy Study. , 2003, 44, 4388.		70

#	ARTICLE	IF	CITATIONS
163	In-Vitro Study of Bacterial Adherence to Different Types of Intraocular Lenses. Drug Development and Industrial Pharmacy, 2002, 28, 95-99.	2.0	24
164	Malignant glaucoma induced by a phakic posterior chamber intraocular lens for myopia. Journal of Cataract and Refractive Surgery, 2002, 28, 2217-2221.	1.5	71
165	In vivo study of bacterial adhesion to five types of intraocular lenses. Investigative Ophthalmology and Visual Science, 2002, 43, 3717-21.	3.3	35
166	Real-Life Efficacy, Safety, and Use of Dexamethasone Intravitreal Implant in Posterior Segment Inflammation Due to Non-infectious Uveitis (LOUVREÂ2 Study). Ophthalmology and Therapy, 0, , .	2.3	11